You are here

Press Statements

Pfizer announces it will defer company’s price increases

Hospira Issues Voluntary Nationwide Recall Of Daptomycin For Injection Lyophilized Powder For Solution, Due to Infusion Reactions

Hospira Issues A Voluntary Nationwide Recall For Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System Due To The Potential Presence of Particulate Matter.

Pfizer Reaches $23.85 Million Settlement Agreement To Resolve Allegations Related To Patient Assistance Charities

Around the World, People Living with Ulcerative Colitis Share Common Perspectives and Experiences

Important Notice Regarding EpiPen auto-injector supply

Dawn Rogers Appointed Executive Vice President of Pfizer Worldwide Human Resources

Hospira Issues A Voluntary Nationwide Recall For Hydromorphone HCL Injection, USP CII Due To The Potential For Empty Or Cracked Glass Vials

Hospira Issues A Voluntary Nationwide Recall For Labetalol Hydrochloride Injection, USP, Due To The Potential Of Cracked Glass At The Rim Surface Of The Vials

Pfizer Teams Up with Sickle Cell Disease Community to Launch New Online Platform

Greenstone Issues Voluntary Nationwide Recall of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP Due to Possible Sub Potent and Super Potent Tablets

Hospira Issues Voluntary Worldwide Recall For Lots of Hydromorphone HCl Injection, USP, CII, (2 mg/mL) 1mg/mL Vial, and Levophed® (Norepinephrine Bitartrate Injection, USP), 4 mg/4 mL (1 mg/mL) Vial, Due to a Lack of Sterility Assurance

Hospira Issues A Voluntary Nationwide Recall For One Lot of Vancomycin Hydrochloride for Injection, USP, 750 mg/vial Due to The Presence of Particulate Matter Within a Single Vial

Pfizer Provides Update on Proposed Epoetin Alfa Biosimilar

Hospira Issues A Voluntary Nationwide Recall For 8.4% Sodium Bicarbonate Injection…

Pfizer Completes Enrollment of Phase 2 Study of Domagrozumab (PF-06252616)in Duchenne Muscular Dystrophy

Hospira Issues a Voluntary Nationwide Recall For One Lot Of 25% Dextrose Injection, USP (Infant) Due To The Presence of Particulate Matter

Pfizer’s Statement On The Misuse Of Our Products In Lethal Injections For Capital Punishment

Pfizer and the National Newspaper Publishers Association Collaborate to Raise Awareness of Sickle Cell Disease and Need for Improved Patient Care

European League Against Rheumatism (EULAR) Includes Janus Kinase (JAK) Inhibitors in Updated Recommendations for the Management of RA

VYNDAQEL® (tafamidis) Receives Approval in Brazil by ANVISA for the Treatment of Transthyretin Familial Amyloid Polyneuropathy

Pfizer Showcases 12 New Data Presentations On Transthyretin Amyloidosis, Increasing Understanding Of A Rare Disease

Hospira Issues A Voluntary Recall For One Lot Of 50% Magnesium Sulfate Injection, USP Due To The Presence Of Particulate

Hospira Issues A Voluntary Recall For One Lot Of Sodium Bicarbonate Injection, USP Due To The Presence Of A Particulate

HOSPIRA ISSUES A VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF MAGNESIUM SULFATE IN WATER FOR INJECTION DUE TO INCORRECT BARCODE LABELING ON THE PRIMARY CONTAINER

Pfizer Joins Broad Effort to Observe National Disability Employment Awareness Month

Pfizer Expands Support for Patients with Gaucher Disease Through New Agreement for ELELYSO

FDA Accepted For Review Pfizer NDA for ADHD Treatment

Pfizer Applauds House of Representatives for Passing the 21st Century Cures Act

Pfizer Wins Jury Verdict in Zoloft Case in Philadelphia

Pfizer Applauds the Committee on Energy and Commerce for Passing the 21st Century Cures Act Today

Pfizer Praises Passage Of New Alabama Legislation

Statement Regarding FDA Advisory Committees’ Vote on CHANTIX®

The Benefits of a Potential Combination with AstraZeneca PLC ("AstraZeneca")

U.S. Appeals Court Upholds Lyrica Patent That Expires On December 30, 2018

Bridget Walsh Appointed Vice President of Federal Government Relations

Pfizer subsidiary Meridian awarded government contract to develop auto-injector medical countermeasure against nerve agent exposure

Pfizer Statement on PhRMA-EFPIA Principles for Responsible Clinical Trial Data Sharing

Pfizer Mourns Loss of Prominent Leader and Respected Board Member

Pfizer Responds to New York Times Article on NIH Policy

Original Statement Provided to New York Times

Pfizer Response To Global Consensus Statement On Menopausal Hormone Therapy

Zithromax (azithromycin) FDA Drug Safety Communication

Pfizer Chairman and Chief Executive Officer Ian Read Issues Statement on White House Meeting

Pfizer Donates Vials of Factor IX to the World Federation of Hemophilia to Help Developing Countries

Findings from the Kronos Early Estrogen Prevention Study (KEEPS), presented today at The North American Menopause Society (NAMS) Annual Meeting in Orlando, Fla.

The U.S. Food and Drug Administration issued a Drug Safety Communication on Revatio®

Pfizer Helpful Answers mourns the loss of actor Lupe Ontiveros

Ongoing Analyses have Helped Re-evaluate Benefit-Risk Profile of Hormone Therapy for Appropriate Menopausal Women

Pfizer Response To Ongoing Evaluation Of Hormone Therapy And Breast Cancer, And What It Means For Menopausal Women Who Have Had A Hysterectomy

Pfizer Joins Innovative Partnership to Eliminate or Control 10 Neglected Tropical Diseases by 2020

Pfizer Statement Responding to Questions on Voluntary Lipitor Contracting Programs

Pfizer applauds U.S. Sens. Pat Leahy (VT) and Charles Grassley (IA) and U.S. Reps. Patrick Meehan (PA) and Linda Sanchez (CA) for introducing the "Counterfeit Drug Penalty Enhancement Act of 2011."

Pfizer announced that the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC)

Pfizer Responds to Analysis in PLoS One, an Online Publication of the Public Library of Science

Pfizer Statement Regarding Lyrica Epilepsty

Pfizer Receives Complete Response Letter From FDA For Moderate-To-Severe Vasomotor Symptoms (VMS) Indication For Pristiq® (desvenlafaxine) Extended Release Tablets.

Pfizer strongly believes in and supports Chantix as an important treatment option.

Pfizer Inc. has received the European Commission Decision to renew the marketing authorization (MA) for Champix® (varenicline tartrate) for a further five year period for the treatment of smoking cessation in adults.

Pfizer has studied Chantix (varenicline) in a randomized, double-blind, placebo-controlled clinical trial in smokers with certain types of cardiovascular disease.

Pfizer Inc.ýs Alpharma LLC subsidiary has decided to suspend sales in the United States of 3-Nitro® (Roxarsone), a feed medicine used primarily in poultry production.

Pfizer takes patient safety and regulatory reporting obligations very seriously. All post-marketing reports of adverse events are reviewed by Pfizer and reported to regulatory agencies, including FDA.

Pfizer is appalled by the allegations of abuse in Libya. We condemn any misuse of our medicines. Pfizer stopped shipping all products to Libya in February, when sanctions were implemented by the international community. Our thoughts remain with the peopl

New Guidelines Announce Lyrica® (pregabalin) Capsules CV — Pfizer is proud that Lyrica® (pregabalin) capsules CV, which is an FDA approved treatment indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN)

Pfizer is not involved in the film's production

Pfizer Statement on Conducting Clinical Trials in Response to the FDA Letter Dated April 9, 2010

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.